Ye Yanshuo, An Yuan, Wang Min, Liu Hongyu, Guan Lianyue, Wang Zhanpeng, Li Wei
Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, People's Republic of China.
Department of Pathology, Jilin Provincial Cancer Hospital, Changchun 130012, People's Republic of China.
Cancer Manag Res. 2020 Mar 31;12:2353-2364. doi: 10.2147/CMAR.S228984. eCollection 2020.
Carboxypeptidase X, M14 family member 2 (CPXM2) has been reported to be involved with several human malignancies. However, the impact of CPXM2 on human hepatocellular carcinoma (HCC) tumorigenesis has not been studied.
Using immunohistochemistry, the detailed CPXM2 expression patterns were examined in HCC cell lines and tissues. Additionally, a hepatic stellate cell line overexpressing CPXM2 and an HCC CPXM2-knockdown cell line were established by lipofection of an expression plasmid or short hairpin RNA, respectively. The transfection efficiencies were confirmed by reverse transcription-quantitative PCR, Western blotting and immunofluorescence. Moreover, Western blotting was conducted to determine the phosphorylation levels of the tyrosine kinase 2 (JAK2)/signal transducer and activator of transcription 3 (Stat1) pathway. Furthermore, gp130-specific hairpin RNA was used to knockdown gp130 expression in hepatic stellate cells overexpressing CPXM2. The malignant phenotype of cultured HCC cells was assessed by a Cell Counting Kit-8 (CCK8) assay, plate cloning assay, Matrigel invasion assay and wound-healing assay in vitro.
It was demonstrated that CPXM2 was upregulated in HCC, and its upregulation predicted a poor prognosis. Besides, the upregulation of CPXM2 markedly enhanced the metastatic potential of HCC via the gp130/JAK2/Stat1 signaling pathway in vitro.
In summary, this evidence suggests a positive role for CPXM2 in HCC progression via modulation of the gp130/JAK2/Stat1 signaling pathway in HCC.
据报道,羧肽酶X,M14家族成员2(CPXM2)与多种人类恶性肿瘤有关。然而,CPXM2对人类肝细胞癌(HCC)肿瘤发生的影响尚未得到研究。
采用免疫组织化学方法,检测CPXM2在肝癌细胞系和组织中的详细表达模式。此外,分别通过转染表达质粒或短发夹RNA建立了过表达CPXM2的肝星状细胞系和CPXM2敲低的肝癌细胞系。通过逆转录定量PCR、蛋白质免疫印迹法和免疫荧光法确认转染效率。此外,采用蛋白质免疫印迹法检测酪氨酸激酶2(JAK2)/信号转导和转录激活因子3(Stat1)通路的磷酸化水平。此外,利用gp130特异性发夹RNA敲低过表达CPXM2的肝星状细胞中gp130的表达。通过细胞计数试剂盒-8(CCK8)检测、平板克隆检测、基质胶侵袭检测和体外伤口愈合检测评估培养的肝癌细胞的恶性表型。
结果表明,CPXM2在肝癌中上调,其上调预示着预后不良。此外,CPXM2的上调在体外通过gp130/JAK2/Stat1信号通路显著增强了肝癌的转移潜能。
总之,该证据表明CPXM2通过调节肝癌中的gp130/JAK2/Stat1信号通路在肝癌进展中发挥积极作用。